CME Credits:
Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen’s University.

Learning Objectives:
- To summarize aspects of recent developments in the understanding of immunotherapy, novel therapeutic agents as these relate to specific malignancies and their therapeutic targets.
- To describe and discuss results of recent Investigational New Drug studies conducted by the CCTG.
- To explain aspects new clinical trial methodologies in the field of early cancer drug development.

9:00 am Welcome

9:05 am IND Team Awards announced
Philippe Bedard

9:10 am Dr. Elizabeth Eisenhauer Early Drug Development Young Investigator Award & Lecture: IND.231
John Hilton

9:40 am CCTG & CRI collaboration
Aiman Shalabi,
Cancer Research Institute

10:10 am Coffee break

10:25 am Trial updates:
  a) IND.228
  b) IND.214
  c) IND.223/224
  d) IND.227
  a) Abha Gupta
  b) Derek Jonker
  c) Kim Chi
  d) Quincy Chu

11:05 am Current trials:
  a) IND.225
  b) IND.226
  c) IND.217
  d) IND.222
  e) IND.224
  f) IND.232
  Lesley Seymour

11:30 am Planned trials:
  a) IND.235
  b) IND.236
  c) Durvalumab rechallenge
  d) CFI-400945 single agent multi-arm PII
  e) CFI-402257 single agent PII
  f) Durvalumab + CFI-400945
  a) – c) Martin Smoragiewicz
  d) – f) David Cescon

11:55am Closing remarks
Philippe Bedard